ClinicalTrials.gg
CompletedNCT06079476Updated Oct 21, 2026Results posted

A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.

A Phase 4 interventional study of Romosozumab in Postmenopausal Osteoporosis, sponsored by Amgen. Completed at 10 sites in India. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Updated Oct 21, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing romosozumab in Osteoporosis, Postmenopausal — 1 open to participants now, 2 under way, none of them phase 3. romosozumab · Osteoporosis, Postmenopausal.

Enrollment
9th of 12
100 · median 268
Started
2023
the only one that year
Phase 4
3 of 12
1 open now
Registered
10th of 12
by date
Lead sponsor
9 of 12
Amgen

Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, this one is the 9th largest by enrollment, is the only one that started in 2023, is one of 3 in phase 4, and was the 10th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 12 studies testing romosozumab in Osteoporosis, Postmenopausal is open now. Recruiting first, the newest first:

About romosozumab

romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing romosozumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

The primary objective of this study is to characterize safety and tolerability of romosozumab in postmenopausal women with osteoporosis and a high risk of fracture in India.

03

Conditions studied

  • Postmenopausal Osteoporosis

Keywords

  • Romosozumab
  • EVENITY®
  • Osteoporosis
  • Women Health
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants diagnosed with osteoporosis who are and have a high risk of fracture who provided inform consent (in-person or through their legally authorized representative) to participate in the use of romosozumab per local label in India.

Exclusion criteria

Exclusion Criteria:

  • Participants who experienced myocardial infarction or stroke within a year prior to entering this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Phase 4: Romosozumab

    Participants will be dosed with two subcutaneous (SC) injections of romosozumab once a month for 12 months.

    Drug: Romosozumab

Interventions

  • Single-use prefilled syringe for SC injection.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical trial participant irrespective of a causal relationship with the trial intervention. If an AE occurred on or after the first dose of trial intervention, the AE was considered to be a TEAE.

    Time frame: From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months

  2. Number of Participants Who Experienced Treatment-emergent Serious Adverse Events (TESAEs)

    An SAE was defined as any untoward medical occurrence that met at least 1 of the following serious criteria: resulted in death (fatal), was immediately life-threatening, required in-patient hospitalization or prolonged existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or other medically important serious event. A TESAE was defined as an SAE that occurred on or after the first dose of trial intervention.

    Time frame: From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months

  3. Number of Participants Who Experienced Clinically Significant Changes in Laboratory Assessments

    Laboratory parameters included: hematology (red blood cell, hemoglobin, platelets, white blood cell count, neutrophils, eosinophils, monocytes, basophils and lymphocytes), chemistry (sodium, potassium, chloride, bicarbonate, total protein, albumin, calcium, albumin-adjusted calcium, magnesium, phosphorus, glucose, blood urea nitrogen or urea, creatinine, total bilirubin, direct bilirubin, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase) and serum 25-hydroxy vitamin D. Clinical significance of laboratory parameters was determined by the investigator.

    Time frame: From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months

  4. Number of Participants Who Experienced Clinically Significant Changes in Vital Signs

    Vital signs included: systolic blood pressure, diastolic blood pressure, heart rate, respiratory rate, and temperature. Clinical significance of vital signs was determined by the investigator.

    Time frame: From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months

Secondary outcomes

  1. Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 6 and Month 12

    Lumbar spine BMD was determined by dual-energy X-ray absorptiometry (DXA). Baseline was defined as last evaluation prior to or on Study Day 1. If results from baseline DXA were not available, the results from scans taken on or before Study Day 14 were considered as baseline values.

    Time frame: Baseline, Month 6 and Month 12

  2. Percent Change From Baseline in Total Hip BMD at Month 6 and Month 12

    Total hip BMD was determined by DXA. Baseline was defined as last evaluation prior to or on Study Day 1. If results from baseline DXA were not available, the results from scans taken on or before Study Day 14 were considered as baseline values.

    Time frame: Baseline, Month 6 and Month 12

  3. Percent Change From Baseline in Femoral Neck BMD at Month 6 and Month 12

    Femoral neck BMD was determined by DXA. Baseline was defined as last evaluation prior to or on Study Day 1. If results from baseline DXA were not available, the results from scans taken on or before Study Day 14 were considered as baseline values.

    Time frame: Baseline, Month 6 and Month 12

07

Results

Posted Oct 21, 2026

Participant flow

This trial was conducted at 10 centers in India from October 2023 to October 2025.

Participant flow — Overall Study
MilestoneRomosozumab 210 mg SC QM
Started100
Completed86
Not completed14
Withdrew: Lost to follow-up2
Withdrew: Withdrawal by subject12

Outcome measures

PrimaryNumber of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical trial participant irrespective of a causal relationship with the trial intervention. If an AE occurred on or after the first dose of trial intervention, the AE was considered to be a TEAE.

Time frame:
From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
ParticipantsRomosozumab 210 mg SC QM
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)73
PrimaryNumber of Participants Who Experienced Treatment-emergent Serious Adverse Events (TESAEs)

An SAE was defined as any untoward medical occurrence that met at least 1 of the following serious criteria: resulted in death (fatal), was immediately life-threatening, required in-patient hospitalization or prolonged existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or other medically important serious event. A TESAE was defined as an SAE that occurred on or after the first dose of trial intervention.

Time frame:
From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsRomosozumab 210 mg SC QM
Number of Participants Who Experienced Treatment-emergent Serious Adverse Events (TESAEs)6
PrimaryNumber of Participants Who Experienced Clinically Significant Changes in Laboratory Assessments

Laboratory parameters included: hematology (red blood cell, hemoglobin, platelets, white blood cell count, neutrophils, eosinophils, monocytes, basophils and lymphocytes), chemistry (sodium, potassium, chloride, bicarbonate, total protein, albumin, calcium, albumin-adjusted calcium, magnesium, phosphorus, glucose, blood urea nitrogen or urea, creatinine, total bilirubin, direct bilirubin, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase) and serum 25-hydroxy vitamin D. Clinical significance of laboratory parameters was determined by the investigator.

Time frame:
From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Clinically Significant Changes in Laboratory Assessments
ParticipantsRomosozumab 210 mg SC QM
Number of Participants Who Experienced Clinically Significant Changes in Laboratory Assessments0
PrimaryNumber of Participants Who Experienced Clinically Significant Changes in Vital Signs

Vital signs included: systolic blood pressure, diastolic blood pressure, heart rate, respiratory rate, and temperature. Clinical significance of vital signs was determined by the investigator.

Time frame:
From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Clinically Significant Changes in Vital Signs
ParticipantsRomosozumab 210 mg SC QM
Number of Participants Who Experienced Clinically Significant Changes in Vital Signs0
SecondaryPercent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 6 and Month 12

Lumbar spine BMD was determined by dual-energy X-ray absorptiometry (DXA). Baseline was defined as last evaluation prior to or on Study Day 1. If results from baseline DXA were not available, the results from scans taken on or before Study Day 14 were considered as baseline values.

Time frame:
Baseline, Month 6 and Month 12
Reported as:
Mean · Percent change
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 6 and Month 12
Percent changeRomosozumab 210 mg SC QM
Month 69.2 ± 0.8
Month 1211.1 ± 0.9
SecondaryPercent Change From Baseline in Total Hip BMD at Month 6 and Month 12

Total hip BMD was determined by DXA. Baseline was defined as last evaluation prior to or on Study Day 1. If results from baseline DXA were not available, the results from scans taken on or before Study Day 14 were considered as baseline values.

Time frame:
Baseline, Month 6 and Month 12
Reported as:
Mean · Percent change
Percent Change From Baseline in Total Hip BMD at Month 6 and Month 12
Percent changeRomosozumab 210 mg SC QM
Month 64.6 ± 0.6
Month 126.1 ± 0.9
SecondaryPercent Change From Baseline in Femoral Neck BMD at Month 6 and Month 12

Femoral neck BMD was determined by DXA. Baseline was defined as last evaluation prior to or on Study Day 1. If results from baseline DXA were not available, the results from scans taken on or before Study Day 14 were considered as baseline values.

Time frame:
Baseline, Month 6 and Month 12
Reported as:
Mean · Percent change
Percent Change From Baseline in Femoral Neck BMD at Month 6 and Month 12
Percent changeRomosozumab 210 mg SC QM
Month 63.4 ± 0.8
Month 125.7 ± 1.1

Adverse events

Collected over All-cause mortality: From enrollment to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months. For AEs: From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Romosozumab 210 mg SC QM0/100 (0%)6/100 (6%)47/100 (47%)
Most frequent serious events
Most frequent serious events
EventRomosozumab 210 mg SC QM
Myocardial infarctionCardiac disorders1/100
CataractEye disorders1/100
GastroenteritisInfections and infestations1/100
Lower respiratory tract infectionInfections and infestations1/100
PneumoniaInfections and infestations1/100
Device looseningProduct Issues1/100
Most frequent other events
Most frequent other events
EventRomosozumab 210 mg SC QM
Injection site painGeneral disorders13/100
PruritusSkin and subcutaneous tissue disorders9/100
Back painMusculoskeletal and connective tissue disorders8/100
AnaemiaBlood and lymphatic system disorders7/100
ArthralgiaMusculoskeletal and connective tissue disorders7/100
ConstipationGastrointestinal disorders5/100
DyspepsiaGastrointestinal disorders5/100
Influenza like illnessGeneral disorders5/100
MyalgiaMusculoskeletal and connective tissue disorders5/100

Baseline characteristics

Full Analysis Set (FAS): Included all participants who enrolled in the trial.

Age, Continuous
Age, Continuous(Years)Romosozumab 210 mg SC QM
Mean63.6 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Romosozumab 210 mg SC QM
Female100
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Romosozumab 210 mg SC QM
Hispanic or Latino0
Not Hispanic or Latino100
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Romosozumab 210 mg SC QM
American Indian or Alaska Native0
Asian100
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

10 sites
  • Stavya Spine Hospital and Research Institute SSHRI
    Ahmedabad, Gujarat 380 007, India
  • MS Ramaiah Medical College and Hospitals
    Bangalore, Karnataka 560054, India
  • King Edward Memorial Hospital And Seth Gordhandas Sunderdas Medical College
    Mumbai, Maharashtra 400012, India
  • Sancheti Institute for Orthopedics and rehabilitation
    Pune, Maharashtra 411005, India
  • Sir Ganga Ram Hospital
    New Delhi, National Capital Territory of Delhi 110060, India
  • Apollo Hospital
    New Delhi, National Capital Territory of Delhi 110076, India
  • Post Graduate Institute of Medical Education and Research
    Chandigarh, Punjab 160 012, India
  • MGM Healthcare
    Chennai, Tamil Nadu 600 029, India
  • Christain Medical College
    Vellore, Tamil Nadu 632004, India
  • King Georges Medical University
    Lucknow, Uttar Pradesh 226 003, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Oct 2025, 23 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 27 phase 4 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2023
First posted
Oct 12, 2023
StartActual
Oct 30, 2023
Primary completionActual
Oct 18, 2025
CompletionActual
Oct 18, 2025
Results first posted
Oct 21, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 21, 2026
Primary outcomes
4 edited
What changed in the outcomes
  • EditedNumber of Participants ExperiencingWho Experienced Treatment-emergent Adverse Events (TEAETEAEs)Time frame: Up to 12 months → From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
  • EditedNumber of Participants ExperiencingWho Experienced Treatment-emergent Serious Adverse Events (TESAETESAEs)Time frame: Up to 12 months → From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
  • EditedNumber of Participants ExperiencingWho Experienced Clinically Significant Changes in Laboratory AssessmentsTime frame: Baseline, Month 12 → From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
  • EditedNumber of Participants WithWho Experienced Clinically Significant Changes in Vital SignsTime frame: Baseline, Month 12 → From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
Oct 21, 2026
Documents
Secondary outcomes
3 added, 3 removed
What changed in the outcomes
  • AddedPercent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 6 and Month 12Time frame: Baseline, Month 6 and Month 12
  • AddedPercent Change From Baseline in Total Hip BMD at Month 6 and Month 12Time frame: Baseline, Month 6 and Month 12
  • AddedPercent Change From Baseline in Femoral Neck BMD at Month 6 and Month 12Time frame: Baseline, Month 6 and Month 12
  • RemovedPercentage Change From Baseline in Bone Mineral Density (BMD) (Measured by Dual-energy X-ray Absorptiometry [DXA]) of the Lumbar SpineTime frame: At 6 months and 12 months
  • RemovedPercentage Change From Baseline in BMD (Measured by DXA) of the Total HipTime frame: At 6 months and 12 months
  • RemovedPercentage Change From Baseline in BMD (Measured by DXA) of the Femoral NeckTime frame: At 6 months and 12 months
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Results posted
    Primary outcomes 4 edited
    What changed in the outcomes
    • EditedNumber of Participants ExperiencingWho Experienced Treatment-emergent Adverse Events (TEAETEAEs)Time frame: Up to 12 months → From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
    • EditedNumber of Participants ExperiencingWho Experienced Treatment-emergent Serious Adverse Events (TESAETESAEs)Time frame: Up to 12 months → From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
    • EditedNumber of Participants ExperiencingWho Experienced Clinically Significant Changes in Laboratory AssessmentsTime frame: Baseline, Month 12 → From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
    • EditedNumber of Participants WithWho Experienced Clinically Significant Changes in Vital SignsTime frame: Baseline, Month 12 → From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
    Secondary outcomes 3 added, 3 removed
    What changed in the outcomes
    • AddedPercent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 6 and Month 12Time frame: Baseline, Month 6 and Month 12
    • AddedPercent Change From Baseline in Total Hip BMD at Month 6 and Month 12Time frame: Baseline, Month 6 and Month 12
    • AddedPercent Change From Baseline in Femoral Neck BMD at Month 6 and Month 12Time frame: Baseline, Month 6 and Month 12
    • RemovedPercentage Change From Baseline in Bone Mineral Density (BMD) (Measured by Dual-energy X-ray Absorptiometry [DXA]) of the Lumbar SpineTime frame: At 6 months and 12 months
    • RemovedPercentage Change From Baseline in BMD (Measured by DXA) of the Total HipTime frame: At 6 months and 12 months
    • RemovedPercentage Change From Baseline in BMD (Measured by DXA) of the Femoral NeckTime frame: At 6 months and 12 months
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06079476
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 12, 2023
Start date
Oct 30, 2023
Primary completion
Oct 18, 2025
Completion
Oct 18, 2025
Results posted
Oct 21, 2026
Last update
Oct 21, 2026

Study contacts

MD
study director · Amgen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romosozumab

Start the discussion